Francois Guilhot spends much of his time researching Internal medicine, Imatinib, Myeloid leukemia, Imatinib mesylate and Surgery. As part of his studies on Internal medicine, Francois Guilhot often connects relevant subjects like Oncology. His Oncology research includes elements of Hematology, Transplantation and Chronic phase chronic myelogenous leukemia.
His study in Imatinib is interdisciplinary in nature, drawing from both Cytarabine, Chronic myelogenous leukemia and Tyrosine-kinase inhibitor. His Myeloid leukemia research incorporates elements of Gastroenterology, Hematologic Response and Minimal residual disease. His Imatinib mesylate study frequently links to adjacent areas such as Myeloid.
His primary scientific interests are in Internal medicine, Imatinib, Imatinib mesylate, Myeloid leukemia and Oncology. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology and Surgery. His biological study deals with issues like Chronic myelogenous leukemia, which deal with fields such as Philadelphia chromosome and Chronic phase chronic myelogenous leukemia.
His research investigates the connection between Imatinib mesylate and topics such as Cytarabine that intersect with issues in Alpha interferon. His Myeloid leukemia research is multidisciplinary, incorporating perspectives in Tyrosine kinase, Leukemia and Tyrosine-kinase inhibitor. The Dasatinib study combines topics in areas such as Nilotinib and Phases of clinical research.
The scientist’s investigation covers issues in Internal medicine, Myeloid leukemia, Oncology, Ponatinib and Imatinib. Internal medicine is represented through his Dasatinib, Adverse effect, Nilotinib, Discontinuation and Imatinib mesylate research. His studies deal with areas such as Tyrosine kinase, Leukemia, Minimal residual disease, Tyrosine-kinase inhibitor and Pharmacology as well as Myeloid leukemia.
His study in Tyrosine-kinase inhibitor is interdisciplinary in nature, drawing from both Chronic myelogenous leukemia and Immunology. His Oncology study combines topics in areas such as Quality of life and Transplantation. His work carried out in the field of Imatinib brings together such families of science as Gastroenterology and Phases of clinical research.
His main research concerns Internal medicine, Myeloid leukemia, Imatinib, Adverse effect and Dasatinib. The study incorporates disciplines such as Surgery and Oncology in addition to Internal medicine. Myeloid leukemia is closely attributed to Leukemia in his research.
His research in Imatinib is mostly focused on Imatinib mesylate. His Adverse effect study incorporates themes from Clinical endpoint, Ponatinib and Cumulative incidence. His Tyrosine-kinase inhibitor research integrates issues from Chronic myelogenous leukemia, European LeukemiaNet, Bosutinib and Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann.
The New England Journal of Medicine (2003)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann.
The New England Journal of Medicine (2006)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot.
The New England Journal of Medicine (2002)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
François-Xavier Mahon;Delphine Réa;Joëlle Guilhot;François Guilhot.
Lancet Oncology (2010)
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman.
Blood (2002)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus.
Blood (2006)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser.
Journal of Clinical Oncology (2009)
Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot.
The New England Journal of Medicine (2003)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker.
Leukemia (2009)
International randomized study of interferon vs STI571 (IRIS) 8-year follow up : Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
Michael Deininger;Stephen G O'Brien;François Guilhot;John M Goldman.
Blood (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Friedrich Schiller University Jena
Augusta University
University of Bologna
The University of Texas MD Anderson Cancer Center
Huntsman Cancer Institute
University of Michigan–Ann Arbor
University of California, San Francisco
Oregon Health & Science University
University of Chicago
Imperial College London
Tel Aviv University
Artois University
Indian Institute of Technology Bombay
LG (United States)
Cornell University
Uppsala University
University of Toronto
Argonne National Laboratory
Huazhong University of Science and Technology
University of Melbourne
University of Bristol
Cornell University
University of Wisconsin–Madison
Chinese Academy of Sciences
Rhodes University
University of Louisville